No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects
Metrics: PDF 337 views | HTML 836 views | ?
Anqi Zhang1,*, Ting-Yan Shi2,*, Yuan Zhao1, Junmiao Xiang1, Danyang Yu1, Zongwen Liang1, Chaoyi Xu1, Qiong Zhang1, Yue Hu1, Danhan Wang1, Jing He1,3 and Ping Duan1
1Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China
2Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
3Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
*These authors have contributed equally to this work
Ping Duan, email: email@example.com
Jing He, email: firstname.lastname@example.org
Keywords: TP53; polymorphism; ovarian cancer; susceptibility; meta-analysis
Received: June 10, 2017 Accepted: November 04, 2017 Published: November 21, 2017
The TP53 gene product is an important regulator of cell growth and a tumor suppressor. The association between TP53 Arg72Pro polymorphism and ovarian cancer risk has been widely investigated, but the results are contradictory. We therefore searched the PubMed, EMBASE and Chinese Biomedical databases for studies on the relation between TP53 Arg72Pro polymorphism and ovarian cancer risk. Our final meta-analysis included 24 published studies with 3271 cases and 6842 controls. Pooled results indicated that there was no significant association between TP53 Arg72Pro polymorphism and ovarian cancer risk [Pro/Pro vs. Arg/Arg: odds ratio (OR) =1.04, 95% confidence interval (CI) = 0.81-1.34; Arg/Pro vs. Arg/Arg: OR = 1.14, 95% CI = 0.96-1.36; recessive: OR = 1.05, 95% CI = 0.90-1.22; dominant: OR = 1.12, 95% CI = 0.94-1.33; and Pro vs. Arg: OR = 1.06, 95% CI=0.93-1.20]. Likewise, stratified analyses failed to reveal a genetic association. Despite some limitations, the present meta-analysis provides statistical evidence indicating a lack of association between TP53 Arg72Pro polymorphism and ovarian cancer risk.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.